Mark John Eribal
Family · New York, NYNPI 1134739907
Payments from drug & device makers
Across 107 payments — averaging $27.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Apellis Pharmaceuticals, Inc.$540
- Johnson & Johnson$324
- Daiichi Sankyo Inc.$257
- Amgen$125
- Seagen Inc.$125
- plus $583 from 11 others
What the payments were for
- Food & beverage$2,79593%
- Education$1957%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 45 | $1,036 |
| Apellis Pharmaceuticals, Inc. | 22 | $540 |
| Johnson & Johnson | 10 | $324 |
| Daiichi Sankyo Inc. | 11 | $257 |
| Amgen | 1 | $125 |
| Seagen Inc. | 1 | $125 |
| AbbVie | 1 | $124 |
| Incyte Corporation | 1 | $100 |
| Sanofi | 3 | $84 |
| Bristol Myers Squibb | 4 | $83 |
| Pharmaessentia USA Corporation | 2 | $56 |
| Karyopharm Therapeutics Inc. | 1 | $33 |
| Pfizer | 1 | $27 |
| Astellas Pharma US Inc | 1 | $24 |
| AstraZeneca | 1 | $20 |
| Bayer | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,990 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 68 | $1,001,608 |
| JakafiRuxolitinib Phosphate | 35 | $566,402 |
| RevlimidLenalidomide | 33 | $533,874 |
| Lenalidomide | 33 | $468,567 |
| IbrancePalbociclib | 20 | $323,648 |
| BrukinsaZanubrutinib | 16 | $244,733 |
| LynparzaOlaparib | 11 | $162,230 |
| EliquisApixaban | 54 | $47,248 |
| XareltoRivaroxaban | 29 | $33,215 |
| Acyclovir | 95 | $1,459 |
| Hydroxyurea | 35 | $1,260 |
| Mycophenolate Mofetil | 14 | $541 |
| Letrozole | 23 | $172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $100 | $566,40235 claims |
| Bristol Myers SquibbRevlimid | $83 | $533,87433 claims |
| PfizerIbrance, Eliquis | $27 | $370,89674 claims |
| AstraZenecaLynparza | $20 | $162,23011 claims |
| Johnson & JohnsonXarelto | $324 | $33,21529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.
Other family in New York
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Mary Sullivan-WhalenNew York$137K
- Leslie WoronaNew York$77K
- Thomas SaglimbeniNew York$48K
- Kathryn JohnsonNew York$48K
- Derek PinedaNew York$38K
- Rebecca SchoriNew York$32K
- Evangelia NezisNew York$22K
- Colette NelsonNew York$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.